Dr. Kelly has authored over 220 peer-reviewed publications published in prominent scientific journals including Science, Nature, Cell, New England Journal of Medicine, Proceedings of the National Academy of Sciences, Journal of the American Chemical Society, Biochemistry, and Journal of Medicinal Chemistry. For reprint requests, please click here.
2005:
- Page LJ, Suk J Y, Huff ME, Lim H-J, Venable J, Yates III J, Kelly JW, Balch WE. Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J. 2005;24:4124-4132.
- Wiseman RL, Powers ET, Kelly JW. Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease. Biochemistry 2005;44:16612-16623.
- Fu Y, Bieschke J, Kelly JW. E-Olefin dipeptide isostere incorporation into a polypeptide backbone enables hydrogen bond perturbation: probing the requirements for Alzheimer's amyloidogenesis. J. Am. Chem. Soc. 2005;127:15366-15367.
- Powers ET, Deechongkit S, Kelly JW. Backbone-backbone H-bonds make context-dependent contributions to protein folding kinetics and thermodynamics: lessons from amide-to-ester mutations. Adv. Protein Chem. 2005;72:39-78.
- Foss TR, Wiseman RL, Kelly JW. The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 2005;44:15525-15533.
- Sawkar AR, Adamski-Werner SL, Cheng W-C, Wong C-H, Beutler E, Zimmer K-P, Kelly JW. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem. Biol. 2005;12:1235-1244.
- Kelly JW. Form and function instructions. Nature 2005;437:486-487.
- Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 2005;38:911-921.
- Green NS, Foss T, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc. Natl. Acad. Sci. USA 2005;102:14545-14550.
- Nguyen H, Jäger M, Kelly JW, Gruebele M. Engineering a β-sheet protein toward the folding speed limit. J. Phys. Chem. B 2005;109:15182-15186.
- Frankenfield KN, Powers ET, Kelly JW. Influence of the N-terminal domain on the aggregation properties of the prion protein. Protein Sci. 2005;14:2154-2166.
- Wiseman RL, Green NS, Kelly JW. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange - implications for transthyretin amyloidosis. Biochemistry 2005;44:9265-9274.
- Premkumar L, Sawkar AR, Boldin-Adamsky S, Toker L, Silman I, Kelly JW, Futerman AH, Sussman JL. X-ray structure of human acid-β-glucosidase covalently bound to conduritol-B-epoxide: implications for Gaucher disease. J. Biol. Chem. 2005;280:23815-23819.
- Zhang Q, Kelly JW. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice. Biochemistry 2005;44:9079-9085.
- Deechongkit S, Powers ET, You S-L, Kelly JW. Controlling the morphology of cross β-sheet assemblies by rational design. J. Am. Chem. Soc. 2005;127:8562-8570.
- Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW. Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry 2005;44:4977-4983.
- You S-L, Kelly JW. Total synthesis of didmolamides A and B. Tetrahedron Lett. 2005;46:2567-2570.
- Petrassi HM, Johnson SM, Purkey HE, Chiang KP, Walkup T, Jiang X, Powers ET, Kelly JW. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. J. Am. Chem. Soc. 2005;127:6662-6671.
- Wiseman RL, Johnson SM, Kelker MS, Foss T, Wilson IA, Kelly JW. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J. Am. Chem. Soc. 2005;127:5540-5551.
- Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005;121:73-85.
- Foss TR, Kelker MS, Wiseman RL, Wilson IA, Kelly JW. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis. J. Mol. Biol. 2005;347:841-854.
- Kelly JW. Attacking amyloid. N. Engl. J. Med. 2005;352:722-723.
- Razavi H, Powers ET, Purkey HE, Adamski-Werner SL, Chiang KP, Dendle MTA, Kelly JW. Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. Bioorg. Med. Chem. Lett. 2005;15:1075-1078.
- Johnson SM, Petrassi HM, Palaninathan SK, Mohamedmohaideen NN, Purkey HE, Nichols C, Chiang KP, Walkup T, Sacchettini JC, Sharpless KB, Kelly JW. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J. Med. Chem. 2005;48:1576-1587.
- You S-L, Kelly JW. The total synthesis of bistratamides F-I. Tetrahedron 2005;61:241-249.
